Coherus BioSciences Company Profile (NASDAQ:CHRS)

About Coherus BioSciences

Coherus BioSciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CHRS
  • CUSIP:
Key Metrics:
  • Previous Close: $30.92
  • 50 Day Moving Average: $30.051
  • 200 Day Moving Average: $22.507
  • 52-Week Range: $12.04 - $31.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.92
  • P/E Growth: 0.000
  • Market Cap: $1.34B
  • Outstanding Shares: 43,380,000
  • Beta: 5.27
Profitability:
  • Net Margins: -591.61%
  • Return on Equity: -1,583.92%
  • Return on Assets: -116.18%
Debt:
  • Debt-to-Equity Ratio: -1.61%
  • Current Ratio: 2.19%
  • Quick Ratio: 2.19%
Additional Links:
Companies Related to Coherus BioSciences:

Analyst Ratings

Consensus Ratings for Coherus BioSciences (NASDAQ:CHRS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.60 (28.07% upside)

Analysts' Ratings History for Coherus BioSciences (NASDAQ:CHRS)
Show:
DateFirmActionRatingPrice TargetDetails
9/17/2016Credit Suisse Group AGSet Price TargetBuy$38.00View Rating Details
9/7/2016Maxim GroupInitiated CoverageBuy$43.00View Rating Details
8/11/2016Barclays PLCReiterated RatingBuy$46.00View Rating Details
7/27/2016Citigroup Inc.Initiated CoverageBuy$36.00View Rating Details
3/1/2016JPMorgan Chase & Co.Lower Price TargetOverweight$37.00 -> $35.00View Rating Details
12/1/2014Cowen and CompanyInitiated CoverageOutperform$45.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Coherus BioSciences (NASDAQ:CHRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q2($1.32)($1.72)$6.87 million$14.07 millionViewListenView Earnings Details
5/9/2016Q1($1.42)($1.67)ViewListenView Earnings Details
2/29/2016Q4($1.74)($1.35)ViewListenView Earnings Details
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details
8/10/2015Q215($1.56)$488.15 millionViewListenView Earnings Details
5/11/2015Q115($1.22)$488.15 millionViewListenView Earnings Details
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details
9/1/2011$0.01($0.01)ViewN/AView Earnings Details
6/2/2011$0.12$0.17ViewN/AView Earnings Details
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)
Current Year EPS Consensus Estimate: $-6.74 EPS
Next Year EPS Consensus Estimate: $-5.22 EPS

Dividends

Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Coherus BioSciences (NASDAQ:CHRS)
Insider Ownership Percentage: 32.88%
Institutional Ownership Percentage: 58.37%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2016Dennis M LanfearInsiderSell4,060$31.75$128,905.00View SEC Filing  
9/16/2016Dennis M LanfearInsiderSell2,900$31.79$92,191.00View SEC Filing  
8/8/2016Fmr LlcInsiderSell100,000$29.86$2,986,000.00View SEC Filing  
8/5/2016Fmr LlcInsiderSell48,600$28.48$1,384,128.00View SEC Filing  
8/1/2016Alan C HermanInsiderSell11,333$25.54$289,444.82View SEC Filing  
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.83View SEC Filing  
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.82View SEC Filing  
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50View SEC Filing  
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50View SEC Filing  
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00View SEC Filing  
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00View SEC Filing  
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17View SEC Filing  
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.00View SEC Filing  
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36View SEC Filing  
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00View SEC Filing  
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87View SEC Filing  
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Coherus BioSciences (NASDAQ:CHRS)
DateHeadline
publicnow.com logoCoherus BioSciences Regains Development and Commercial Rights to CHS-0214 From Shire (NASDAQ:CHRS)
www.publicnow.com - September 27 at 8:47 AM
biz.yahoo.com logoCOHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ (NASDAQ:CHRS)
biz.yahoo.com - September 26 at 4:26 PM
4-traders.com logoCoherus BioSciences : Management to Present at Two Investor Healthcare Conferences in September (NASDAQ:CHRS)
www.4-traders.com - September 24 at 8:27 AM
News IconNews review of 2 biotech stocks: Coherus Biosciences, Inc. (NASDAQ:CHRS), Inovio Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:CHRS)
voiceregistrar.com - September 21 at 8:15 AM
capitalcube.com logoETF’s with exposure to Coherus BioSciences, Inc. : September 19, 2016 (NASDAQ:CHRS)
www.capitalcube.com - September 19 at 5:00 PM
forbes.com logoNotable Friday Option Activity: CHRS, TWTR, PBYI - Forbes (NASDAQ:CHRS)
www.forbes.com - September 18 at 8:54 AM
thestreet.com logoAbbVie's Battle Royale (NASDAQ:CHRS)
www.thestreet.com - September 14 at 8:27 AM
News IconThe Sell-side Consensus is in on Coherus BioSciences, Inc. (NASDAQ:CHRS); Earnings & Target Updates - National Daily Press (NASDAQ:CHRS)
www.nationaldailypress.com - September 9 at 9:01 AM
News IconPlacing Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Under the Microscope - Post News (NASDAQ:CHRS)
www.kentuckypostnews.com - September 8 at 5:34 AM
News IconTrading the Biotech News: Coherus Biosciences, Inc. (NASDAQ:CHRS), Ophthotech Corporation (NASDAQ:OPHT) - The Voice Registrar (NASDAQ:CHRS)
voiceregistrar.com - September 7 at 9:16 PM
globenewswire.com logoCoherus BioSciences Announces New Employment Inducement Grants - GlobeNewswire (press release) (NASDAQ:CHRS)
globenewswire.com - September 2 at 4:01 PM
publicnow.com logoCoherus BioSciences Management to Present at Two Investor Healthcare Conferences in September (NASDAQ:CHRS)
www.publicnow.com - September 1 at 4:07 PM
blogs.barrons.com logo3 Biotech Biosimilar Winners (NASDAQ:CHRS)
blogs.barrons.com - September 1 at 4:07 PM
publicnow.com logoCoherus BioSciences Announces New Employment Inducement Grants (NASDAQ:CHRS)
www.publicnow.com - September 1 at 12:20 PM
capitalcube.com logoETF’s with exposure to Coherus BioSciences, Inc. : August 29, 2016 (NASDAQ:CHRS)
www.capitalcube.com - August 29 at 3:35 PM
News IconIs it Time to Buy Coherus BioSciences, Inc. (NASDAQ:CHRS)? Crowd & Analysts Weigh in - Post News (NASDAQ:CHRS)
www.kentuckypostnews.com - August 24 at 11:00 AM
finance.yahoo.com logoCOHERUS BIOSCIENCES, INC. Financials (NASDAQ:CHRS)
finance.yahoo.com - August 18 at 4:14 PM
capitalcube.com logoETF’s with exposure to Coherus BioSciences, Inc. : August 15, 2016 (NASDAQ:CHRS)
www.capitalcube.com - August 15 at 11:27 AM
capitalcube.com logoCoherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:CHRS)
www.capitalcube.com - August 12 at 11:49 AM
nasdaq.com logoCoherus BioSciences Submits 351(k) Biologics License Application to U.S. Food ... (NASDAQ:CHRS)
www.nasdaq.com - August 10 at 10:25 PM
fortune.com logoAnalyst Ratings Worth Watching: Coherus Biosciences Inc ... - Review Fortune (NASDAQ:CHRS)
reviewfortune.com - August 10 at 10:46 AM
rttnews.com logoEARNINGS SUMMARY: Details of Coherus Biosciences, Inc. Q2 Earnings Report (NASDAQ:CHRS)
www.rttnews.com - August 9 at 10:00 PM
streetinsider.com logoCoherus BioSciences (CHRS) Announces CHS-1420 Phase 3 Met Primary Endpoint (NASDAQ:CHRS)
www.streetinsider.com - August 9 at 10:00 PM
sg.finance.yahoo.com logoCoherus BioSciences reports 2Q loss (NASDAQ:CHRS)
sg.finance.yahoo.com - August 9 at 10:00 PM
nasdaq.com logoCommit To Purchase Coherus BioSciences At $20, Earn 9% Annualized Using Options (NASDAQ:CHRS)
www.nasdaq.com - August 9 at 4:30 PM
News IconCoherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar… (NASDAQ:CHRS)
forextv.com - August 9 at 4:30 PM
finance.yahoo.com logoCoherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration … (NASDAQ:CHRS)
finance.yahoo.com - August 9 at 4:30 PM
streetinsider.com logoCoherus BioSciences (CHRS) Announces Submission of CHS-1701 BLA to U.S. FDA Under 351(k) Pathway (NASDAQ:CHRS)
www.streetinsider.com - August 9 at 4:30 PM
twst.com logoCoherus BioSciences Inc.: Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:CHRS)
www.twst.com - August 9 at 4:30 PM
publicnow.com logoCoherus BioSciences Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:CHRS)
www.publicnow.com - August 9 at 4:30 PM
biz.yahoo.com logoCoherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:CHRS)
biz.yahoo.com - August 9 at 4:30 PM
News IconCoherus Biosciences Inc (NASDAQ:CHRS): Check on Earnings - Post Registrar (NASDAQ:CHRS)
postregistrar.com - August 9 at 12:01 PM
streetinsider.com logoCoherus BioSciences (CHRS) Announces CHS-1420 Phase 3 Met Primary Endpoint - StreetInsider.com (NASDAQ:CHRS)
www.streetinsider.com - August 9 at 12:01 PM
biz.yahoo.com logoQ2 2016 Coherus BioSciences Inc Earnings Release - After Market Close (NASDAQ:CHRS)
biz.yahoo.com - August 9 at 12:01 PM
nasdaq.com logoCoherus Announces Positive Results For CHS-1420 In Patients With Psoriasis (NASDAQ:CHRS)
www.nasdaq.com - August 8 at 8:59 AM
publicnow.com logoCoherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis (NASDAQ:CHRS)
www.publicnow.com - August 8 at 8:59 AM
ftsenews.co.uk logoCoherus BioSciences, Inc. (CHRS) Updated Price Targets - FTSE News (NASDAQ:CHRS)
www.ftsenews.co.uk - August 5 at 4:14 PM
tradecalls.org logoCitigroup Initiates Coverage on Coherus Biosciences Inc to Buy ... - Trade Calls (NASDAQ:CHRS)
www.tradecalls.org - August 3 at 4:17 PM
ftsenews.co.uk logoBrokers Issue Average Price Target Of 37.40 On Coherus BioSciences, Inc. (CHRS) - FTSE News (NASDAQ:CHRS)
www.ftsenews.co.uk - July 29 at 9:40 PM
benzinga.com logoCiti Analyst Sees 45-60% Upside In Coherus Biosciences (NASDAQ:CHRS)
www.benzinga.com - July 27 at 12:49 PM
finance.yahoo.com logoCoverage initiated on Coherus BioSciences by Citigroup (NASDAQ:CHRS)
finance.yahoo.com - July 27 at 6:36 AM
publicnow.com logoCoherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th (NASDAQ:CHRS)
www.publicnow.com - July 25 at 11:18 AM
News IconChecking in on Stock Volatility for: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Engelwood Daily (NASDAQ:CHRS)
www.engelwooddaily.com - July 22 at 4:15 PM
News IconCoherus Biosciences Inc on Focus After Crashing In Today's Session - Consumer Eagle (NASDAQ:CHRS)
www.consumereagle.com - July 22 at 4:15 PM
News IconEquity Roundup: Stock Performance Focus on Coherus BioSciences, Inc. (NASDAQ:CHRS) - Press Telegraph (NASDAQ:CHRS)
presstelegraph.com - July 22 at 4:15 PM
News IconCoherus BioSciences, Inc. (NASDAQ:CHRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:CHRS)
www.engelwooddaily.com - July 22 at 4:15 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Coherus BioSciences, Inc. (NASDAQ:CHRS) - TGP (NASDAQ:CHRS)
telanaganapress.com - July 21 at 7:01 AM
News IconCoherus Biosciences Inc Just Recorded A Sigfniciant Increase - Press Telegraph (NASDAQ:CHRS)
presstelegraph.com - July 21 at 7:01 AM
News IconShares Jumping Higher in Session: Coherus Biosciences, Inc. (NASDAQ:CHRS) - TGP (NASDAQ:CHRS)
telanaganapress.com - July 20 at 5:21 PM
News IconCoherus Biosciences Incorporated (NASDAQ:CHRS) Sellers Increased By 2.15% Their Shorts - Consumer Eagle (NASDAQ:CHRS)
www.consumereagle.com - July 20 at 12:14 PM

Social

Coherus BioSciences (NASDAQ:CHRS) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff